From its Phase 2b research at the ERS Annual Congress in Amsterdam.

The two podium presentations review the results from the Company’s two clinical trials of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis patients. Placebo. The primary endpoint – the mean change in Pseudomonas aeruginosa CFUs from baseline to day time 28 – was fulfilled in the full analysis human population with both 2 mL and 3 mL dosages vs. Placebo.. Aradigm announces two ciprofloxacin Stage 2b study data on non-CF bronchiectasis Aradigm Company today announced it is presenting data on September 26, 2011, from its Phase 2b research at the ERS Annual Congress in Amsterdam, Netherlands.For Assisted Main Patency Rate at twelve months, Artegraft was 60 % and ePTFE was 20 %, according to the scholarly study results. After 2 yrs, the Assisted Primary Price was 40 % for Artegraft and 14 % for ePTFE. Study results also concluded that there were much less thrombosis and fewer interventions with the Artegraft BCA, as well as no pseudoaneurysms. Related StoriesStudy: Post hospital syndrome is significant risk factor for patients going through elective surgeryGlan Clwyd Medical center N Wales invest in Esaote's G-Scan MRI unit for weight-bearing scanningBoston Kids's and Rock Health synergy to accelerate advancement of pediatric health technology The analysis validates the results that leading surgeons who’ve used Artegraft have experienced for 40 years, said Richard A.